Leucid Bio United States of America United Kingdom England

Initiation of AERIAL trial accelerated by successful first close of Series A1 financing LEU011 is first CAR-T candidate for the treatment of solid tumours to be manufactured at Great Ormond Street Hospital (GOSH) Enrolment continues in AERIAL trial with initial data for LEU011 expected in the second half of 2025under the identifier NCT06193902.

About Leucid Bio

Leucid Bio is a privately-held biotechnology company dedicated to the development of cell therapies for the treatment of solid tumours using the Company's proprietary lateral CAR platform. The Company's lead asset, LEU011, is an autologous CAR-T cell therapy targeting NKG2D ligands, which are expressed on more than 80% of human tumours. In addition, LEU011 co-expresses the chemokine receptor CXCR2 which is engineered to enhance cell trafficking and tumour infiltration. For more information, please visit the Leucid Bio website at www.leucid.com.

About Great Ormond Street Hospital for Children NHS Foundation Trust

Great Ormond Street Hospital is one of the world's leading children's hospitals with the broadest range of dedicated, children's healthcare specialists under one roof in the UK. The hospital's pioneering research, innovation and treatment gives hope to children from across the UK and the world with the rarest, most complex and often life-threatening conditions.

GOSH is home to the Zayed Centre for Research into Rare Disease in Children, which brings together pioneering research and world-leading clinical care to drive new tests, treatments and cures for rare and complex diseases from lab bench to bedside. The Cell and Gene Therapy Facility within the Zayed Centre for Research is comprised of seven bespoke laboratories and provides comprehensive facilities for all stages of manufacture.

View original content:https://www.prnewswire.co.uk/news-releases/leucid-bio-announces-treatment-of-first-patient-in-aerial-trial-of-nkg2d-car-t-therapy-leu011-for-solid-tumours-302452160.html